| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Letters to the Editor |
Hyogo Prefectural Amagasaki Hospital Hyogo, Japan
Donald F. Sellitti and
Uniformed Services University of Health Sciences Bethesda, Maryland
Sonia Q. Doi, Takashi Akamizu and Kazuwa Nakao
Kyoto University Graduate School of Medicine Kyoto, Japan
In a recent article, Khoo et al. (1) reported a family, in which activating TSH receptor (TSH-R) mutation is associated with mitral valve prolapse. They concluded that TSH-R activation may increase the clinical expression of mitral valve prolapse in genetically predisposed individuals.
As the authors stated, mitral valve prolapse in a relatively common disorder, but its real prevalence as a disease entity is controversial. It was earlier reported by Channick et al. (2) that mitral valve prolapse is associated with hyperthyroidism due to Graves disease, which was confirmed by other investigators (3). Because the affected members with gain-of-function mutations of the TSH-R described by Khoo et al. were all thyrotoxic, it is reasonable to speculate that mitral valve prolapse is secondary to thyrotoxicosis caused by TSH-R activation. In this context, it seems likely that mitral valve prolapse is not specific to the TSH-R mutation.
The cardiac manifestations in hyperthyroidism have been attributed to the direct effects of thyroid hormone or its indirect effects through catecholamines on the heart. As Khoo et al. commented in their discussion (1), Drvota et al. (4) and we (5, 6) have reported the presence of TSH-R in the heart. We postulate that cardiomyopathy is another clinical presentation of Graves disease, which may be mediated through autoimmunity against the TSH-R (5). The involvement of adjacent myocardium is suggested in some cases with mitral valve prolapse (2). Considering that mitral valve prolapse is associated with Hashimotos thyroiditis (7), it remains possible that some autoimmune mechanisms may underlie the mitral valve prolapse, as well as cardiomyopathy, associated with autoimmune thyroid diseases.
Footnotes
Address all correspondence to: Dr. Hiroyuki Koshiyama, Division of Endocrinology and Metabolism, Department of Internal Medicine, Hyogo Prefectural Amagasaki Hospital, 1-1-1 Higashi-Damitosu-cho, Amagasaki, Hyogo 660-0828, Japan.
Received May 11, 1999.
References
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |